Drugs in Neurology

2. Auflage 2025
ISBN: 978-0-19-886969-6
Verlag: Oxford University Press

Buch, Englisch, 792 Seiten, Format (B × H): 100 mm x 173 mm, Gewicht: 522 g

Part of the Drugs in series, this easily accessible pocket-sized guide covers the optimal use of medications when treating patients with neurological ailments. This second edition of Drugs in Neurology outlines the indications, contra-indications, side-effects, and important interactions of each drug. Since the publication of the first Drugs in Neurology, a revolution in the neurological sciences has been underway with numerous previously untreatable conditions, receiving disease modifying research.

This edition has been updated in its entirety to mirror the significant progress made in each field of neurology, including new drug profiles on emerging/recently licensed agents and a new chapter covering Neurogenetics.

Practical aspects related to prescribing and therapeutic drug monitoring are explored and based on the most up-to-date evidence-based guidance. This practical handbook is relevant to neurology and neurosurgery registrars in training, consultants, general practitioners, general physicians, junior doctors, specialist nurses, pharmacists, and medical students.

Autoren/Hrsg.

Weitere Mitwirkende

Nageshwaran, Sathiji

Ledingham, David

Wilson, Heather

Inhaltsverzeichnis

- Section 1 - Neurological conditions

- 1: Headache

- 2: Vertigo

- 3: Epilepsy

- 4: Cerebrovascular disease

- 5: Neuropathic pain

- 6: Multiple sclerosis and related disorders

- 7: Other inflammatory disorders of the central nervous system

- 8: Disorders of peripheral nerves

- 9: Motor neuron disease

- 10: Disorders of muscle

- 11: Disorders of the neuromuscular junction

- 12: Parkinson's disease and parkinsonism

- 13: Hyperkinetic movement disorders

- 14: Dementia

- 15: Spasticity

- 16: Neuro- oncology

- 17: Sleep disorders

- 18: Neurological infections

- 19: Metabolic disorders

- 20: Uro- neurology

- 21: Drugs causing neurological disease

- 22: Neurogenetics

- Section 2 - Drugs

- 23: Drug Classes

- 24: A- Z Index of neurological drugs

Über Autor(innen)

Sathiji K Nageshwaran completed his medical training at University College London and doctoral work at Imperial College London, synthetic biology training in the lab of George Church at Harvard Medical School and residency in Neurology at Mount Sinai Hospital. He is currently a Neurogenetics Fellow at UCLA in the lab of Daniel Geschwind.

David Ledingham completed his medical training at the University of Cambridge and University College London. He is currently a Consultant Neurologist at Newcastle Hospitals and is an Honorary Senior Lecturer at Newcastle University. His clinical interests include movement disorders, deep brain stimulation and botulinum toxin injections. He is actively involved in research and clinical trials in the fields of Parkinson's disease, atypical Parkinson's and dystonia.

Dr Heather Wilson is a senior consultant neurologist who joined the MS team at the National Hospital for Neurology and Neurosurgery at UCL in 2020, after working as a general neurologist and MS specialist at the Royal Free NHS Foundation Trust for 16 years. She has experience in managing all aspects of Multiple Sclerosis including all of the licensed disease-modifying therapies, and is committed to MS service development and optimisation.
She graduated from Guy's Hospital Medical School in 1990 and undertook her Neurology specialist training in London (King's College Hospital, NHNN and the Royal Free Hospital). She has a PhD in Neuro-immunology from Cambridge University and has an ongoing interest in the immunopathology of MS. She is nationally recognised in the field of MS and reglarly speaks on the topic at national and local levels.